Loading
BP2201 is an experimental iPS cell-derived NKT cell therapy from BrightPath Biotherapeutics, in phase 1 trials for head and neck cancer; its current status is not stated.
BP2201 is an iPS cell-derived NKT cell therapy (allogeneic) from BrightPath Biotherapeutics. Allogeneic NKT cells regenerated from iPS cells, which can kill cancer cells directly and activate other immune cells. Its furthest stage is phase 1, for head and neck cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Company page says a phase 1 in head and neck cancer showed initial safety and clinical activity; no ClinicalTrials.gov entry found. It has not been shown to work in people.
Allogeneic NKT cells regenerated from iPS cells, which can kill cancer cells directly and activate other immune cells.
1.BP2201 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BP2201" OR ABSTRACT:"BP2201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BP2201, not a curated reading list.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/